We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


3 August 2010 By Pierre Briancon

The French pharmaceutical group has approached the US biotech company with a $18 billion offer, according to Reuters. That’s less than what Genzyme is trading at, and is unlikely to be accepted. But Sanofi needs Genzyme’s pipeline and growth, and it can afford to sweeten its bid.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)